A Novel Development of Sarcoidosis Following COVID-19 Vaccination and a Literature Review.
Intern Med
; 61(20): 3101-3106, 2022 Oct 15.
Article
in English
| MEDLINE | ID: covidwho-2079920
ABSTRACT
BNT162b2 (Pfizer/BioNTech) is a coronavirus disease 2019 (COVID-19) vaccine containing nucleoside-modified messenger RNA encoding the severe acute respiratory syndrome coronavirus 2 spike glycoprotein. Recently, ocular complications of mRNA vaccines have been reported increasingly frequently. However, immunological adverse events due to mRNA vaccines in real-world settings are not fully known. We herein report the novel development of sarcoidosis manifested as uveitis, bilateral hilar lymphadenopathy, angiotensin-converting enzyme elevation, and epithelioid and giant cell granuloma formation in the lung soon after the first BNT162b2 injection and review the current literature, including three reported cases of sarcoid-like reaction following COVID-19 vaccination.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Sarcoidosis
/
COVID-19 Vaccines
/
COVID-19
Type of study:
Case report
/
Observational study
/
Reviews
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Intern Med
Journal subject:
Internal Medicine
Year:
2022
Document Type:
Article
Affiliation country:
Internalmedicine.0104-22
Similar
MEDLINE
...
LILACS
LIS